| Literature DB >> 28534993 |
Chun-Yan Wang1, Yong-Xiang Fang1, Guo-Hua Chen1, Huai-Jie Jia1, Shuang Zeng1, Xiao-Bing He1, Yuan Feng1, Shou-Jie Li1, Qi-Wang Jin1, Wen-Yu Cheng1, Zhi-Zhong Jing1.
Abstract
The T cell receptor (TCR) is a complex heterodimer that recognizes fragments of antigens as peptides and binds to major histocompatibility complex molecules. The TCR α and β chains possess three hypervariable regions termed complementarity determining regions (CDR1, 2 and 3). CDR3 is responsible for recognizing processed antigen peptides. Immunoscope spectratyping is a simple technique for analyzing CDR3 polymorphisms and sequence length diversity, in order to investigate T cell function and the pattern of TCR utilization. The present study employed this technique to analyze CDR3 polymorphisms and the sequence length diversity of TCR α and β chains in porcine CD4+ and CD8+ T cells. Polymerase chain reaction products of 19 TCR α variable regions (AV) and 20 TCR β variable regions (BV) gene families obtained from the CD4+ and CD8+ T cells revealed a clear band following separation by 1.5% agarose gel electrophoresis, and each family exhibited >8 bands following separation by 6% sequencing gel electrophoresis. CDR3 spectratyping of all identified TCR AV and BV gene families in the sorted CD4+ and CD8+ T cells by GeneScan, demonstrated a standard Gaussian distribution with >8 peaks. CDR3 in CD4+ and CD8+ T cells demonstrated different expression patterns. The majority of CDR3 recombined in frame and the results revealed that there were 10 and 14 amino acid discrepancies between the longest and shortest CDR3 lengths in specific TCR AV and TCR BV gene families, respectively. The results demonstrated that CDR3 polymorphism and length diversity demonstrated different expression and utilization patterns in CD4+ and CD8+ T cells. These results may facilitate future research investigating the porcine TCR CDR3 gene repertoire as well as the functional complexity and specificity of the TCR molecule.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28534993 PMCID: PMC5482108 DOI: 10.3892/mmr.2017.6601
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
Primer sequences used for TCR AV/BV-specific amplifications.
| A, TCR AV family | ||
|---|---|---|
| Variable region | Primer sequence (5′-3′) | Expected size (bp) |
| DV1 | TGGCTGGAATGCAAAGGAAGA | 220 |
| AV2S | TCAGGTGCAGGTGGCAGATG | 150 |
| AV3S | CCAGCTGTCCTAGGGAGCGACT | 150 |
| AV4S | GGCCACCCTGAAAGACACTGC | 210 |
| AV5S | AAAATCACAGCAGCCCAACCTG | 153 |
| AV6S | GAGCACCACCTTTGACACCAGAG | 200 |
| AV8-3S | TCCAGTACCCCAGCCAAGGA | 280 |
| AV8-4S | CAGAGGCTTTGGGGCTGAAT | 270 |
| AV12S | GCAAGCATGTCTCCCTGCTCA | 170 |
| AV13S | CTCCCTGCACATCGCAGTCA | 170 |
| AV14 | TCTCAGATGCACAGGTGGAGGA | 160 |
| AV16S | CCTCGACAAGAAAGAGGCATCC | 200 |
| AV18S | TCTTCCAGAGGAGGCACCTATGAC | 350 |
| AV21S | CGAGAGGGAGACGGCTTGGT | 340 |
| AV22 | GGCGGCCTCATCAATCTGTTT | 250 |
| AV25S | GGACAGCTCCCTGCACATCA | 160 |
| AV26 | TCGGCAAAATCCCAATCAGA | 280 |
| AV38 | AGCTTCCCAACGGGGAGATG | 270 |
| AV39 | ACCAAAGCCCATTGCAGCAC | 180 |
| AVX | TCGACAGTATCCAAATCAGGCACT | 280 |
| AC-FAM | TTTGGGGCCTTTCAGCTGGT | |
| AC forward | CTGTGATGCCAAGTTGGTAG | 135 |
| AC reverse | CACAGCCGCAGTGTCATGAG | |
| B, TCR BV family | ||
| Variable region | Primer sequence (5′-3′) | Expected size (bp) |
| BV2S | GGCACGTACCTGACTCTGAA | 190 |
| BV3S | ACAGTTCCACGTCGCTTCTT | 220 |
| BV4S | CAGATACCTGGTCCTGGGAA | 370 |
| BV5S | CACCGAGACATCTGATTAAAGC | 380 |
| BV6S | TGGCATCACTGACAAAGGAG | 250 |
| BV7S | TCTGAGCTGAAATTGCTCTCC | 190 |
| BV9S | AGCTTTTGTCTCCACAGGTCA | 400 |
| BV10S | CCTGTGATGTTGGCATCCTT | 260 |
| BV11S | TGTTTCTCAGTTGCCCCAGA | 210 |
| BV12S | CACCCAGACACGAGGTGA | 340 |
| BV12A | CAACAACGGGTCTCCTGTG | 230 |
| BV15S | CGGCCTAACCCTTCTTTCTG | 210 |
| BV19S | CATTGACGCAGAAGAACCAG | 200 |
| BV20 | ACAGCGCCAAGTTTCTCATC | 230 |
| BV21 | ACAGCGATTTACAGCCGAGT | 210 |
| BV24[ | CTTTGTGGCCTTTTGCATCC | 420 |
| BV25 | CACCAGCCCTTCACAGACAT | 180 |
| BV27 | AGCCGAATTTCCCCTTGAT | 190 |
| BV29 | ACCGTCAGCTTCTAGGACAAAG | 390 |
| BV30 | TGACCAGAAAGATCCTGAAAAG | 400 |
| BVXS | ATCCCTTCCTGGAGCAGATT | 220 |
| BC-FAM | ATCTCCGCTTCCGATGGT | |
| BC forward | GGACCTGCAGCAGGTGAGAC | 110 |
| BC reverse | GTAGAAGCCTGTGGCCAGGC | |
Primer sequence is different to those used in the references provided in the materials and methods section. TCR, T cell receptor; AV, α variable region; BV, β variable region; AC, α chain, BC, β chain; FAM, carboxyfluorescein.
Figure 1.The distribution profile of complementarity determining region 3 length in 19 TCR AV families and 20 TCR BV families from healthy miniature pigs. (A) RT-PCR products of 19 TCR AV gene families in separated CD4+ T cells. Lane M represents the DNA ladder, and lanes 1–20 represent the following TCR AV families: DV1, AV2S, AV3S, AV4S, AV5S, AV6S, AV8-3S, AV8-4S, AV12S, AV13S, AV14, AV16S, AV18S, AV21S, AV22, AV25S, AV26, AV38, AV39 and AVX, respectively. (B) RT-PCR products of 20 TCR BV gene families in separated CD4+ T cells. Lane M represents the DNA ladder and lanes 1–21 represent the following TCR BV families: BV2S, BV3S, BV4S, BV5S, BV6S, BV7S, BV9S, BV10S, BV11S, BV12S, BV12A, BV15S, BV19S, BV20, BV21, BV24, BV25, BV27, BV29, BV30 and BVXS, respectively. (C) Numbers 1–20 denote the corresponding RT-PCR products of TCR AV families from DV1 to AVX, separated on a 6% acrylamide sequencing gel. (D) Numbers 1–21 denote the corresponding RT-PCR products of TCR BV families from BV2S to BVXS, separated on a 6% acrylamide sequencing gel. The blue bands represent the PCR products of the TCR gene families. TCR AV, T cell receptor α variable region; TCR BV, T cell receptor β variable region; CD, cluster of differentiation; RT-PCR, reverse transcription-polymerase chain reaction.
Figure 2.CDR3 spectratypes in healthy miniature pigs. (A) CDR3 spectratypes of 19 TCR AV and 20 TCR BV families from CD4+ and CD8+ T cells were analyzed. The x-axis of each plot corresponds to the molecular size of the DNA, and the relative fluorescence intensity of the peaks is plotted on the y-axis. (B) CDR3 fragment size and fluorescence intensity analysis of TCR AV3S, AV8-3S, BV2S and BV3S in CD4+ T cells. Results are representative of results in CD4+ and CD8+ T cells. CDR3, complementarity determining region 3; TCR AV, T cell receptor α variable region; TCR BV, T cell receptor β variable region; CD, cluster of differentiation; FAM, carboxyfluorescein.
GeneScan analysis of CDR3 length in CD4+ and CD8+ T cells of TCR AV families.
| A, CD4+ T cells, bp | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DV 1 | AV 2S | AV 3S | AV 4S | AV 5S | AV 6S | AV 8-3S | AV 8-4S | AV 12S | AV 13S | AV 14S | AV 16S | AV 18S | AV 21 | AV 22 | AV 25 | AV 26 | AV 38 | AV 39 | AV XS |
| 223 | 141 | 144 | 138 | 135 | 194 | 270 | 203 | 171 | 158 | 149 | 182 | 345 | 337 | 252 | 158 | 264 | 267 | 184 | 272 |
| 226 | 144 | 147 | 141 | 138 | 197 | 273 | 206 | 174 | 161 | 152 | 185 | 348 | 340 | 255 | 161 | 267 | 270 | 275 | |
| 229 | 147 | 150 | 144 | 200 | 276 | 209 | 177 | 164 | 155 | 188 | 351 | 343 | 258 | 164 | 270 | 273 | 278 | ||
| 232 | 153 | 145 | 203 | 279 | 212 | 180 | 167 | 158 | 191 | 354 | 346 | 167 | 273 | 276 | 187 | 281 | |||
| 235 | 154 | 156 | 151 | 148 | 206 | 282 | 215 | 183 | 170 | 161 | 194 | 349 | 263 | 170 | 276 | 279 | 284 | ||
| 238 | 157 | 159 | 154 | 151 | 209 | 218 | 186 | 173 | 164 | 197 | 359 | 352 | 266 | 173 | 279 | 282 | 287 | ||
| 241 | 160 | 162 | 157 | 154 | 212 | 287 | 221 | 189 | 176 | 167 | 200 | 362 | 269 | 176 | 282 | 190 | |||
| 244 | 163 | 165 | 160 | 157 | 215 | 290 | 224 | 170 | 203 | 365 | 179 | 287 | 292 | ||||||
| 168 | 163 | 160 | 182 | 287 | 295 | ||||||||||||||
| 163 | 185 | ||||||||||||||||||
| 166 | 188 | ||||||||||||||||||
| 169 | |||||||||||||||||||
| B, CD8+ T cells, bp | |||||||||||||||||||
| DV 1 | AV 2S | AV 3S | AV 4S | AV 5S | AV 6S | AV 8-3S | AV 8-4S | AV 12S | AV 13S | AV 14S | AV 16S | AV 18S | AV 21 | AV 22 | AV 25 | AV 26 | AV 38 | AV 39 | AV XS |
| 225 | 144 | 140 | 138 | 153 | 194 | 266 | 198 | 168 | 158 | 149 | 182 | 339 | 337 | 246 | 164 | 268 | 267 | 192 | 275 |
| 228 | 147 | 143 | 141 | 156 | 197 | 269 | 201 | 171 | 161 | 152 | 185 | 342 | 340 | 249 | 167 | 271 | 270 | 195 | 278 |
| 231 | 150 | 144 | 159 | 200 | 272 | 204 | 174 | 164 | 155 | 188 | 345 | 343 | 252 | 170 | 274 | 273 | 198 | 281 | |
| 234 | 153 | 150 | 203 | 275 | 207 | 177 | 167 | 158 | 191 | 348 | 346 | 255 | 173 | 276 | 201 | 284 | |||
| 237 | 153 | 151 | 163 | 206 | 278 | 210 | 180 | 170 | 161 | 194 | 351 | 349 | 258 | 176 | 279 | 279 | 204 | 287 | |
| 240 | 157 | 156 | 154 | 166 | 209 | 281 | 183 | 173 | 164 | 197 | 354 | 352 | 179 | 282 | 282 | 207 | |||
| 160 | 159 | 157 | 169 | 284 | 214 | 186 | 176 | 167 | 200 | 357 | 355 | 263 | 182 | 285 | 285 | 292 | |||
| 162 | 160 | 172 | 287 | 217 | 189 | 179 | 170 | 203 | 360 | 358 | 266 | 288 | 295 | ||||||
| 165 | 163 | 290 | 206 | 363 | 269 | ||||||||||||||
| 366 | |||||||||||||||||||
The majority of CDR3 sequences in the TCR AV families recombined in-frame. However, out-of-frame gene rearrangements were additionally observed. Particular families demonstrated a 1–2 bp discrepancy (the numbers representing CDR3 sequence length were indicated with italic, underline and bold) and others exhibited ≥4 bp discrepancy (indicated with italic and bold). CDR3, complementarity determining region 3; TCR AV, T cell receptor α variable region.
GeneScan analysis of CDR3 length in the CD4+ and CD8+ T cells of TCR BV families.
| A, CD4+ T cells, bp | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BV2S | BV3S | BV4S | BV5S | BV6S | BV7S | BV9S | BV10S | BV11S | BV12S | BV12AS | BV15S | BV19S | BV20 | BV21 | BV24 | BV25 | BV27 | BV29 | BV30 | BVXS |
| 182 | 215 | 369 | 372 | 238 | 176 | 415 | 248 | 199 | 376 | 248 | 190 | 157 | 211 | 207 | 430 | 150 | 181 | 291 | 235 | 217 |
| 185 | 218 | 372 | 375 | 241 | 179 | 418 | 251 | 202 | 379 | 251 | 193 | 160 | 214 | 210 | 433 | 153 | 184 | 294 | 238 | 220 |
| 188 | 221 | 378 | 244 | 421 | 254 | 205 | 254 | 196 | 163 | 217 | 436 | 156 | 187 | 297 | 241 | 223 | ||||
| 191 | 224 | 380 | 381 | 247 | 184 | 424 | 257 | 208 | 384 | 257 | 199 | 166 | 220 | 217 | 159 | 190 | 300 | 244 | 226 | |
| 194 | 227 | 383 | 250 | 187 | 427 | 260 | 211 | 387 | 202 | 169 | 223 | 220 | 441 | 162 | 193 | 303 | 247 | 229 | ||
| 386 | 386 | 253 | 190 | 430 | 214 | 390 | 262 | 205 | 172 | 226 | 223 | 165 | 196 | 306 | 250 | 232 | ||||
| 199 | 234 | 389 | 389 | 256 | 193 | 433 | 265 | 217 | 393 | 265 | 175 | 226 | 448 | 168 | 199 | 309 | 253 | 235 | ||
| 202 | 237 | 392 | 392 | 259 | 196 | 436 | 268 | 396 | 268 | 212 | 178 | 233 | 229 | 451 | 171 | 202 | 312 | 256 | 238 | |
| 240 | 395 | 395 | 439 | 271 | 227 | 271 | 215 | 181 | 236 | 232 | 174 | 315 | 241 | |||||||
| 442 | 184 | 239 | 235 | 458 | ||||||||||||||||
| 236 | 187 | 461 | ||||||||||||||||||
| 239 | 190 | 464 | ||||||||||||||||||
| 242 | ||||||||||||||||||||
| 245 | ||||||||||||||||||||
| B, CD8+ T-cells, bp | ||||||||||||||||||||
| BV2S | BV3S | BV4S | BV5S | BV6S | BV7S | BV9S | BV10S | BV11S | BV12S | BV12AS | BV15S | BV19S | BV20 | BV21 | BV24 | BV25 | BV27 | BV29 | BV30 | BVXS |
| 182 | 225 | 370 | 377 | 241 | 178 | 415 | 248 | 202 | 372 | 248 | 193 | 160 | 211 | 211 | 430 | 153 | 181 | 286 | 232 | 217 |
| 185 | 228 | 373 | 380 | 244 | 181 | 418 | 251 | 205 | 375 | 251 | 196 | 163 | 214 | 214 | 433 | 156 | 184 | 289 | 235 | 220 |
| 188 | 231 | 376 | 383 | 184 | 421 | 254 | 208 | 378 | 254 | 199 | 166 | 217 | 217 | 436 | 159 | 187 | 292 | 238 | 223 | |
| 234 | 379 | 386 | 247 | 186 | 424 | 257 | 381 | 257 | 202 | 169 | 220 | 220 | 439 | 162 | 190 | 295 | 241 | 226 | ||
| 193 | 237 | 382 | 389 | 250 | 189 | 427 | 260 | 211 | 384 | 205 | 172 | 223 | 223 | 442 | 165 | 193 | 244 | 229 | ||
| 240 | 385 | 392 | 253 | 430 | 387 | 262 | 208 | 175 | 226 | 168 | 196 | 300 | 247 | 232 | ||||||
| 200 | 243 | 388 | 256 | 433 | 265 | 217 | 390 | 265 | 211 | 178 | 230 | 229 | 451 | 171 | 199 | 303 | 250 | 265 | ||
| 203 | 391 | 259 | 436 | 268 | 220 | 393 | 268 | 214 | 233 | 232 | 174 | 202 | 306 | 253 | 268 | |||||
| 206 | 439 | 271 | 217 | 236 | 235 | 309 | 256 | 241 | ||||||||||||
| 209 | 238 | 238 | 312 | 259 | ||||||||||||||||
| 241 | 315 | |||||||||||||||||||
| 244 | ||||||||||||||||||||
The majority of CDR3 sequences in the TCR BV families recombined in-frame. However, out-of-frame gene rearrangement was additionally observed. Particular families demonstrated a 1–2 bp discrepancy (the numbers representing CDR3 sequence length were indicated with italic, underline and bold) and others exhibited ≥4 bp discrepancy (indicated with italic and bold). CDR3, complementarity determining region 3; TCR BV, T cell receptor β variable region.
Figure 3.Differential mean fluorescence intensities of CDR3 in TCR AV and TCR BV families in the CD4+ and CD8+ T cells of healthy miniature pigs. (A) The expression frequency of CDR3 in (A) TCR AV and (B) TCR BV gene families in CD4+ and CD8+ T cells. (C) The MFI ratio of CD4+ and CD8+ T cells within the same gene family. *P<0.05 and **P<0.01 vs. CD8+ T-cell subset. CDR3, complementarity determining region 3; TCR AV, T cell receptor α variable region; TCR BV, T cell receptor β variable region; CD, cluster of differentiation; MFI, mean fluorescence intensity.